Currently, there is no evidence to support transmission of COVID-19 associated with imported goods, including food and drugs for humans and pets. There have not been any cases of COVID-19 in the United States associated with imported goods.
No. Antibiotics do not work against viruses; they only work on bacterial infections. Antibiotics do not prevent or treat coronavirus disease (COVID-19), because COVID-19 is caused by a virus, not bacteria. Some patients with COVID-19 may also develop a bacterial infection, such as pneumonia. In that case, a health care professional may treat the bacterial infection with an antibiotic.
Based on a review of the scientific evidence, chloroquine phosphate and hydroxychloroquine sulfate are unlikely to be effective in treating COVID-19. In light of ongoing serious cardiac adverse events and other potential serious side effects of these treatments in COVID-19 patients, the known and potential benefits no longer outweigh the known and potential risks for use.
The FDA revoked an emergency use authorization for use of hydroxychloroquine sulfate and chloroquine phosphate as a COVID-19 treatment on June 15, 2020 based on FDA’s review of the scientific evidence.
At this time, there are no FDA-approved drug products to treat COVID-19. The FDA is working with drug manufacturers and investigational new drug sponsors to expedite the development and availability of COVID-19 treatments. Read more about FDA’s actions to address the novel coronavirus with medical countermeasures.
Researchers are studying new drugs and drugs that are already approved for other health conditions as possible treatments for COVID-19. CDC has more information for health care providers about these potential treatments.
At this time there is no vaccine to prevent coronavirus disease 2019 (COVID-19). The FDA is working with vaccine developers and other researchers and manufacturers to help expedite the development and availability of medical products such as vaccines, antibodies, and drugs to prevent COVID-19. Read more about what the FDA is doing to mitigate the effects of COVID-19.
The FDA has been closely monitoring the supply chain with the expectation that the COVID-19 outbreak would likely impact the medical product supply chain, including potential disruptions to supply or shortages of critical medical products in the U.S.
We have been reaching out to manufacturers as part of our approach to identifying potential disruptions or shortages. We will use all available tools to react swiftly and mitigate the impact to U.S. patients and health care professionals when a potential disruption or shortage is identified.
Find real-time information about drug shortages.
Learn more in our drug shortages frequently asked questions.
Preliminary data from a Phase 3 study conducted by the USG demonstrated that hospitalized patients with COVID-19 who received remdesivir recovered faster than similar patients who received a placebo. A different Phase 3 study evaluating 5-day and 10-day dosing durations of remdesivir in hospitalized patients with severe COVID-19 (most patients were not receiving mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at baseline), found that a 5-day treatment course had a similar treatment effect as a 10-day treatment course. The safety and efficacy of remdesivir for treatment of COVID-19 is currently being evaluated in multiple clinical trials.
In vitro (laboratory) testing of remdesivir also shows it is active against SARS-CoV-2, the virus that causes COVID-19.
Because remdesivir may help hospitalized patients with severe COVID-19, FDA authorized its use under an Emergency Use Authorization (EUA) issued on May 1, 2020. Under the EUA, health care providers and patients are provided with information about the risks of remdesivir. However, additional evidence from clinical trials are necessary to determine whether the drug is safe and effective in treating or preventing COVID-19.
At this point, there are no vaccines or cures for COVID-19 available to the public, so you know that any claim to the contrary is false. In fact, the Federal Trade Commission has sent hundreds of warning letters to companies making false cure, treatment, or prevention claims. And more letters are on the way. If you see a product claiming to treat, cure, or prevent coronavirus, report it to the FTC at ftc.gov/complaint.
No. Products marketed for veterinary use, “for research only,” or otherwise not for human consumption have not been evaluated for safety or effectiveness and should never be used by humans. FDA is aware that chloroquine phosphate is marketed to treat disease in aquarium fish, but these products have not been evaluated by FDA to determine if they are safe, effective, properly manufactured, and adequately labeled. The agency continues to work with online marketplaces to remove these items, and many have been removed based on these efforts. Patients should not take any form of chloroquine unless it has been prescribed by a licensed health care provider. Chloroquine products also should not be given to pets or livestock unless prescribed by a veterinarian.
No. While there are approved uses for ivermectin in people and animals, it is not approved for the prevention or treatment of COVID-19. You should not take any medicine to treat or prevent COVID-19 unless it has been prescribed to you by your health care provider and acquired from a legitimate source.
A recently released research article described the effect of ivermectin on SARS-CoV-2 in a laboratory setting. These types of laboratory studies are commonly used at an early stage of drug development. Additional testing is needed to determine whether ivermectin might be appropriate to prevent or treat coronavirus or COVID-19. Read more about ivermectin.
We have established a cross-agency task force dedicated to closely monitoring for fraudulent COVID-19 products. We have reached out to major retailers to ask for their help in monitoring online marketplaces for fraudulent COVID-19 products. Products sold are subject to FDA investigation and potential enforcement action if they claim to prevent, diagnose, treat, or cure COVID-19 and have not demonstrated safety and effectiveness for that intended use. The task force has already worked with retailers to remove dozens of these types of product listings online.
The FDA and the Federal Trade Commission (FTC) issue warning letters to companies that violate federal law and pose significant risks to patient health by selling unapproved products with fraudulent claims to treat or prevent COVID-19. View the warning letters for more information.
No. Miracle Mineral Solution does not cure COVID-19 and has not been approved by the FDA for any use. The solution, when mixed, develops into a dangerous bleach which has caused serious and potentially life-threatening side effects. For more information, see: FDA warns consumers about the dangerous and potentially life threatening side effects of Miracle Mineral Solution and Danger: Don’t Drink Miracle Mineral Solution or Similar Products.